Filgrastim-Treated Donor Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia
Status:
Completed
Trial end date:
2002-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Transplanted peripheral stem cells can sometimes be rejected by the body's
tissues. Treating donor peripheral stem cells with filgrastim may increase the number of
donor white blood cells. This may help to decrease the rejection of the transplanted cells in
patients receiving them as treatment for acute leukemia.
PURPOSE: Phase II trial to study the effectiveness of filgrastim-treated donor peripheral
stem cells in treating patients with acute leukemia who are undergoing peripheral stem cell
transplantation.